The clinical success of specific immune checkpoint blockade, such as PD-1 and CTLA-4 (negative regulators of T-cell adaptive immune function), represent a promising advance in cancer immunotherapy development (Pardoll, 2012). Here, CTLA4 is linked to cancer.